Abstract
Dysregulated protein kinase activity can cause severe human diseases. Consequently, there is a growing number of kinases that constitute candidate targets for pharmaceutical intervention. However, target validation is critical, since not all kinases are “druggable”, i.e. suitable as a selective drug target. In this review, we briefly introduce major strategies for generating mouse models to analyse and control the expression and function of distinct genes, to confirm specific inhibition of intended drug targets and to identify undesirable secondary effects in vivo. Focussing on tyrosine kinase 2 (Tyk2) and other Janus kinases (Jaks) as case studies we follow the path of investigations from in vitro towards in vivo experimentation. We give examples for the sometimes surprising consequences of the systemic absence of a distinct kinase; consequences that can not be easily deduced solely based on results from in vitro data. We discuss aspects of kinase functions that are distinct from their catalytic activity and give examples for cell-type specific functions. Potential pitfalls (e.g. embryonic lethality, species differences) of using mouse models as experimental systems for studying human diseases are discussed and strategies for improvements to deal with such complications are exemplified.
Keywords: Jak protein tyrosine kinases, cytokines, drug target, in vivo, mouse models, species differences
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: In Vivo Target Validation: Methodology and Case Studies on the Janus Kinase Tyk2
Volume: 6 Issue: 1
Author(s): Christian Gausterer, Mathias Muller and Birgit Strobl
Affiliation:
Keywords: Jak protein tyrosine kinases, cytokines, drug target, in vivo, mouse models, species differences
Abstract: Dysregulated protein kinase activity can cause severe human diseases. Consequently, there is a growing number of kinases that constitute candidate targets for pharmaceutical intervention. However, target validation is critical, since not all kinases are “druggable”, i.e. suitable as a selective drug target. In this review, we briefly introduce major strategies for generating mouse models to analyse and control the expression and function of distinct genes, to confirm specific inhibition of intended drug targets and to identify undesirable secondary effects in vivo. Focussing on tyrosine kinase 2 (Tyk2) and other Janus kinases (Jaks) as case studies we follow the path of investigations from in vitro towards in vivo experimentation. We give examples for the sometimes surprising consequences of the systemic absence of a distinct kinase; consequences that can not be easily deduced solely based on results from in vitro data. We discuss aspects of kinase functions that are distinct from their catalytic activity and give examples for cell-type specific functions. Potential pitfalls (e.g. embryonic lethality, species differences) of using mouse models as experimental systems for studying human diseases are discussed and strategies for improvements to deal with such complications are exemplified.
Export Options
About this article
Cite this article as:
Gausterer Christian, Muller Mathias and Strobl Birgit, In Vivo Target Validation: Methodology and Case Studies on the Janus Kinase Tyk2, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2007; 6 (1) . https://dx.doi.org/10.2174/187152307779939697
DOI https://dx.doi.org/10.2174/187152307779939697 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role of Inflammation and Allergy in Acute Coronary Syndromes
Inflammation & Allergy - Drug Targets (Discontinued) Dipeptidyl Peptidase-4 Inhibitor Induced Angioedema – An Overlooked Adverse Drug Reaction?
Current Diabetes Reviews Patent Selections:
Recent Patents on Inflammation & Allergy Drug Discovery Classical Inhibitors of NOX NAD(P)H Oxidases Are Not Specific
Current Drug Metabolism Low Concentration of Caffeine Inhibits the Progression of the Hepatocellular Carcinoma <i>via Akt</i> Signaling Pathway
Anti-Cancer Agents in Medicinal Chemistry Novel Biomarkers for Lupus Nephritis in the “OMICS” Era
Current Medicinal Chemistry Efficacy and Cardiovascular Safety of SGLT2 Inhibitors
Current Drug Safety The ACE2-Ang-(1-7)-Mas Axis and Cardioprotection
Current Cardiology Reviews Angiotensin II-Vasopressin Interactions in The Regulation of Cardiovascular Functions. Evidence for an Impaired Hormonal Sympathetic Reflex in Hypertension and Congestive Heart Failure
Endocrine, Metabolic & Immune Disorders - Drug Targets Hormonal, Metabolic and Hemodynamic Adaptations to Glycosuria in Type 2 Diabetes Patients Treated with Sodium-Glucose Co-Transporter Inhibitors
Current Diabetes Reviews HCN Channel as Therapeutic Targets for Heart Failure and Pain
Current Topics in Medicinal Chemistry Transcatheter Aortic Valve Technology: Current State
Recent Patents on Biomedical Engineering (Discontinued) Triptan-Induced Torsades de Pointes and Ventricular Fibrillation Cardiac Arrest: Case Report and Review of the Literature
Current Drug Safety Propofol: Therapeutic Indications and Side-Effects
Current Pharmaceutical Design Exercise Induced Cardioprotection: An Overview of a Unique Form of Preconditioning
Current Cardiology Reviews State of the Art Clinical Efficacy and Safety Evaluation of N-Acetylcarnosine Dipeptide Ophthalmic Prodrug. Principles for the Delivery, Self-Bioactivation, Molecular Targets and Interaction with a Highly Evolved Histidyl-Hydrazide Structure in the Treatment and Therapeutic Management of a Group of Sight-Threatening Eye Diseases
Current Clinical Pharmacology The mTOR Signaling Network: Insights from Its Role During Embryonic Development
Current Medicinal Chemistry Pharmacological Management of Hypertension in the Elderly - Certitudes and Controversies
Current Pharmaceutical Design Tetracyclines: Drugs with Huge Therapeutic Potential
Mini-Reviews in Medicinal Chemistry The Effect of Resveratrol dose and Duration of Treatment on Blood Pressure in Patients with Cardiovascular Disorders: A Systematic Review
Current Drug Discovery Technologies